Publications by authors named "Michael Staehler"

Claim this Profile
D
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.
Daniel D Shapiro, Edwin Jason Abel, Laurence Albiges, Dena Battle, Stephanie A Berg, Michael Staehler

Urol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT.
Peter J Goebell, Martin Bögemann, Arnd Nusch, Viktor Grünwald, Lothar Müller, Michael Staehler

Int J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of SABR in Uncommon Subtypes of Primary Kidney Cancer: An Analysis From the International Radiosurgery Oncology Consortium of the Kidney.
Muhammad Ali, Rohann J M Correa, David Pryor, Braden Higgs, Swetha Sridharan, Michael Staehler

Int J Radiat Oncol Biol Phys· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal Cell Carcinoma: Prognosis in the Era of Targeted Therapy.
Kathrin Halfter, Michael Staehler, Dieter Hölzel, Alexander Crispin, Anne Schlesinger-Raab

Curr Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes of Prostate-Specific Membrane Antigen-Radioligand Uptake on PET with Systemic Therapy in Patients with Metastatic Renal Cell Carcinoma.
Sophie Carina Kunte, Adrien Holzgreve, Marcus Unterrainer, Josef Zahner, Hans Peter Schmid, Michael Staehler

Cancers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial.
Viktor Grünwald, Rana R McKay, Tomas Buchler, Masatoshi Eto, Se Hoon Park, Michael Staehler

Int J Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Perspective on Medical Conditions Post Immune Checkpoint Therapy in Advanced Renal Carcinoma.
Ulka Vaishampayan, Sumanta Pal, Sephora Dafinescu, Neha Shah, Dena Battle, Michael Staehler

J Kidney Cancer VHL· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative Outcomes After Radical Nephrectomy with Inferior Vena Cava Thrombectomy.
Nikolaos Pyrgidis, Gerald Bastian Schulz, Christian G Stief, Iulia Blajan, Troya Ivanova, Michael Staehler

Cancers (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE).
Michael Staehler, Umberto Basso, Jean-Christophe Eymard, Philippe Barthelemy, Pierre Bigot

Clin Genitourin Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of Robotic Urology in Clinical Practice from the Beginning to Now: Results from the GRAND Study Register.
Nikolaos Pyrgidis, Yannic Volz, Benedikt Ebner, Thilo Westhofen, Michael Staehler

Eur Urol Focus· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the Kidney.
Vivian S Tan, Rohann J M Correa, Andrew Warner, Muhammad Ali, Alexander Muacevic, Michael Staehler

Eur Urol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Financial Distress in Genitourinary Cancer: Insights From CDC National Health Interview Survey.
Steven Leonard, Emma Helstrom, Andres Correa, Mohit Sindhani, Nicole Uzzo, Michael Staehler

JCO Oncol Pract· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accuracy of robotic radiosurgery in renal cell carcinoma.
Theresa Hofmann, Nadja Kohlhase, Dochka Eftimova, Michael Martin Eder, Michael Staehler

Phys Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology.
Giulia Marvaso, Barbara Alicja Jereczek-Fossa, Mattia Zaffaroni, Maria Giulia Vincini, Giulia Corrao, Michael Staehler

Lancet Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy.
Hedyeh Ebrahimi, Dena Battle, Nicholas J Salgia, Zeynep B Zengin, Nazli Dizman, Michael D Staehler

Nutrients· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up in Patients Undergoing Renal Mass Biopsy: Seeding is not Anecdotal.
Michael Staehler, Severin Rodler, Isabel Brinkmann, Christian G Stief, Annabel Graser

Clin Genitourin Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Right Tool for the Job: The Knife, the SABR, or Fire and Ice?
Shankar Siva, Michael Staehler

Int J Radiat Oncol Biol Phys· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical Trends and Complications in Partial and Radical Nephrectomy: Results from the GRAND Study.
Nikolaos Pyrgidis, Gerald Bastian Schulz, Christian Stief, Iulia Blajan, Troya Ivanova, Michael Staehler

Cancers (Basel)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches.
Vinh Ngoc Bui, Lena M Unterrainer, Matthias Brendel, Sophie C Kunte, Adrien Holzgreve, Michael Staehler

Biomedicines· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
Robert J Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Zurawski, Michael Staehler

Target Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma.
Marie Mikuteit, Stefanie Zschäbitz, Christine Stöhr, Edwin Herrmann, Iris Polifka, Michael Staehler

Urol Int· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robotic stereotactic body radiotherapy for localized prostate cancer: final analysis of the German HYPOSTAT trial.
David Krug, Detlef Imhoff, Alfred Haidenberger, Nicole Heßler, Jane Schäfer, Michael Staehler

Strahlenther Onkol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative differentiation of minimal-fat angiomyolipomas from renal cell carcinomas using grating-based x-ray phase-contrast computed tomography: An ex vivo study.
Lorenz Birnbacher, Margarita Braunagel, Marian Willner, Mathias Marschner, Fabio De Marco, Michael Staehler

PLoS One· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Robert J Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Zurawski, Michael Staehler

Lancet· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Toni K Choueiri, Masatoshi Eto, Robert Motzer, Ugo De Giorgi, Tomas Buchler, Michael Staehler

Lancet Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis